Illumina Inc ILMN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval
-
Bloom Energy was just named to the S&P 500. These other stocks are joining the index as well.
-
A spot is opening up in the S&P 500, and these stocks are top candidates to fill the void
-
This once-hot cancer-detection company's stock got cut in half after a failed trial
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 151.00M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 54.33
- Price/Sales
- 9.59
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 1.17%
Company Profile
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 8,650
- Website
- https://www.illumina.com
Competitors
Valuation
|
Metric
|
ILMN
|
TMO
|
|---|---|---|
Price/Earnings (Normalized) | 54.33 | 27.38 |
Price/Book Value | 14.57 | 4.58 |
Price/Sales | 9.59 | 5.28 |
Price/Cash Flow | 33.22 | 24.07 |
Price/Earnings
ILMN
TMO
Financial Strength
|
Metric
|
ILMN
|
TMO
|
|---|---|---|
Quick Ratio | 1.22 | 1.01 |
Current Ratio | 1.80 | 1.55 |
Interest Coverage | 10.96 | 5.57 |
Quick Ratio
ILMN
TMO
Profitability
|
Metric
|
ILMN
|
TMO
|
|---|---|---|
Return on Assets (Normalized) | 6.73% | 8.26% |
Return on Equity (Normalized) | 16.79% | 17.21% |
Return on Invested Capital (Normalized) | 9.37% | 10.33% |
Return on Assets
ILMN
TMO
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|zB%Dq@X | LOCK|>N! | $242B | |||
| Danaher Corp
DHR
| LOCK|>q! | LOCK|%g | $150B | |||
| Agilent Technologies Inc
A
| LOCK|WjbFKR%& | LOCK|@X! | $47B | |||
| IQVIA Holdings Inc
IQV
| LOCK|VgDc#y | LOCK|ksf@n | $43B | |||
| Waters Corp
WAT
| LOCK|@Mn#T!% | LOCK|PD | $42B | |||
| Illumina Inc
ILMN
| LOCK|@>GPD% | LOCK|$S&Y? | $41B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|n@%>x^v | LOCK|BZ# | $41B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|>JKf>n! | LOCK|Ky@> | $30B | |||
| Quest Diagnostics Inc
DGX
| LOCK|Tr<XpR% | LOCK|xZJf@ | $26B | |||
| Labcorp Holdings Inc
LH
| LOCK|GrZF>D& | LOCK|?Y??T | $25B |
United States